Shots:
- Madrigal has secured an exclusive global license from CSPC to develop, manufacture, & commercialize SYH2086 for advancing innovative combination therapies targeting MASH
- As per the deal, CSPC will receive $120M upfront & ~$2B in development, regulatory & commercial milestones, with net sales-based royalties; CSPC may also develop other oral GLP-1s in China under certain conditions, with deal closing expected in Q4’25
- SYH2086 is a novel oral GLP-1 receptor agonist & orforglipron derivative that is in preclinical development, with Madrigal planning to begin trials in H1’26
Ref: Globenewswire | Image:Madrigal Pharmaceuticals| Press Release
Related News:- Madrigal Pharmaceuticals’ Rezdiffra Receives the CHMP’s Positive Opinion for MASH with Liver Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
